

02  
CDT

5577, and 6308), inverted relative to their normal orientation for transcription - i.e., antisense CYP2A6 nucleic acid molecules. Such antisense nucleic acid molecules may be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed with CYP2A6 mRNA or the CYP2A6 gene. The antisense sequences may be produced biologically using an expression vector introduced into cells in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense sequences are produced under the control of a high efficiency regulatory region, the activity of which may be determined by the cell type into which the vector is introduced.--

---

At page 12, line 25 extending to page 13, line 2, please replace the current paragraph with the following replacement paragraph:

---

03

--Substances which inhibit transcription and/or translation of the gene encoding CYP2B6 include a nucleic acid sequence encoding the CYP2B6 gene (see Figure 2B, GenBank Accession No. HSP452B6 for the mRNA sequence of CYP2B6 (SEQ ID NO:2), or parts thereof (e.g., the region which is on either side of nucleotide 9 (ATG), and the sites 111, 274, 424, 585, 762, 904, 1092, and 1234 nt), inverted relative to their normal orientation for transcription - i.e., antisense CYP2B6 nucleic acid molecules. Such antisense nucleic acid molecules may be produced and introduced into cells using conventional procedures as described herein.--

---

At page 46, lines 12-18, please replace the Table with the following replacement Table:

Sequence data for antisense oligodeoxynucleotides

NAME*	START*	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	END	SEQ ID NO
ASO#15	-25	T	A	G	A	G	G	G	A	T	G	A	T	A	G	A	T	G	G	T	G	A	C	-4	3
ASO#13	171	C	T	T	C	A	T	G	A	G	G	G	A	G	T	T	G	T	A	C				189	4
ASO#25	190	G	G	C	C	A	T	A	G	C	G	C	T	C	A	C	T	G	A	T				208	5
ASO#23	333	C	C	A	T	A	G	C	C	T	T	T	G	A	A	G	A	C	C	C	A	G		353	6
MSO#23	333	C	C	C	C	A	G	C	C	T	T	T	G	A	A	G	A	C	A	T	A	G		353	7